129 related articles for article (PubMed ID: 19186057)
1. Water-soluble prodrugs of an Aurora kinase inhibitor.
Oslob JD; Heumann SA; Yu CH; Allen DA; Baskaran S; Bui M; Delarosa E; Fung AD; Hashash A; Hau J; Ivy S; Jacobs JW; Lew W; Maung J; McDowell RS; Ritchie S; Romanowski MJ; Silverman JA; Yang W; Zhong M; Fuchs-Knotts T
Bioorg Med Chem Lett; 2009 Mar; 19(5):1409-12. PubMed ID: 19186057
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent and selective aurora kinase inhibitor.
Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
[TBL] [Abstract][Full Text] [Related]
3. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
4. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
5. 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Zhong M; Bui M; Shen W; Baskaran S; Allen DA; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris SO; Heumann SA; Hoch U; Ivy SN; Jacobs JW; Lam S; Lee H; McDowell RS; Oslob JD; Purkey HE; Romanowski MJ; Silverman JA; Tangonan BT; Taverna P; Yang W; Yoburn JC; Yu CH; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2009 Sep; 19(17):5158-61. PubMed ID: 19646866
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S
J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062
[TBL] [Abstract][Full Text] [Related]
7. Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against Gram-positive pathogens.
Fu L; Jiang Z; Cai Z; Liu X; He H; Yang Y
Bioorg Med Chem Lett; 2009 Sep; 19(18):5407-10. PubMed ID: 19682897
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog.
Lee J; Bae S; Lee SH; Choi H; Kim YH; Kim SJ; Park GT; Moon SK; Kim DH; Lee S; Ahn SK; Choi NS; Lee KJ
Bioorg Med Chem Lett; 2010 Nov; 20(21):6327-30. PubMed ID: 20850313
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
10. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828.
Binderup E; Björkling F; Hjarnaa PV; Latini S; Baltzer B; Carlsen M; Binderup L
Bioorg Med Chem Lett; 2005 May; 15(10):2491-4. PubMed ID: 15863303
[TBL] [Abstract][Full Text] [Related]
11. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
12. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
13. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
DeGoey DA; Grampovnik DJ; Flosi WJ; Marsh KC; Wang XC; Klein LL; McDaniel KF; Liu Y; Long MA; Kati WM; Molla A; Kempf DJ
J Med Chem; 2009 May; 52(9):2964-70. PubMed ID: 19348416
[TBL] [Abstract][Full Text] [Related]
14. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
[TBL] [Abstract][Full Text] [Related]
15. Disulfide prodrugs of albitiazolium (T3/SAR97276): synthesis and biological activities.
Caldarelli SA; Hamel M; Duckert JF; Ouattara M; Calas M; Maynadier M; Wein S; Périgaud C; Pellet A; Vial HJ; Peyrottes S
J Med Chem; 2012 May; 55(10):4619-28. PubMed ID: 22591034
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.
Ohsumi K; Hatanaka T; Nakagawa R; Fukuda Y; Morinaga Y; Suga Y; Nihei Y; Ohishi K; Akiyama Y; Tsuji T
Anticancer Drug Des; 1999 Dec; 14(6):539-48. PubMed ID: 10834274
[TBL] [Abstract][Full Text] [Related]
17. Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
Sams AG; Mikkelsen GK; Larsen M; Langgård M; Howells ME; Schrøder TJ; Brennum LT; Torup L; Jørgensen EB; Bundgaard C; Kreilgård M; Bang-Andersen B
J Med Chem; 2011 Feb; 54(3):751-64. PubMed ID: 21210664
[TBL] [Abstract][Full Text] [Related]
18. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Fancelli D; Moll J; Varasi M; Bravo R; Artico R; Berta D; Bindi S; Cameron A; Candiani I; Cappella P; Carpinelli P; Croci W; Forte B; Giorgini ML; Klapwijk J; Marsiglio A; Pesenti E; Rocchetti M; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Zugnoni P; Vianello P
J Med Chem; 2006 Nov; 49(24):7247-51. PubMed ID: 17125279
[TBL] [Abstract][Full Text] [Related]
19. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
Krise JP; Charman WN; Charman SA; Stella VJ
J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
[TBL] [Abstract][Full Text] [Related]
20. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
VanderPorten EC; Taverna P; Hogan JN; Ballinger MD; Flanagan WM; Fucini RV
Mol Cancer Ther; 2009 Apr; 8(4):930-9. PubMed ID: 19372566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
